In this setting, main molecular markers investigated in AML patients include IDH, FLT3 (Fms-Like Tyrosine Kinase 3), c-KIT, Ras, NPM1 (Nucleophosmin 1), ASXL1 (Additional sex comb-like 1), CEBPA (CCAAT Enhancer Binding Protein α), RUNX1 (Run-related transcription factor), DNMT3A (DNA methyltransferase 3A), TET2 (Ten-eleven translocation), WT1 (Wilm’s tumor), and TP53 (Tumor Protein) (Figure 3). This evidence concerns the gene IDH1 and Nephroblastoma.